<ARTICLE> 5 <LEGEND> Exhibit 27 Financial Data Schedule Mylan Laboratories Inc. and Subsidiaries Article 5 of Regulation S-X The schedule contains summary financial information extracted from the Consolidated Balance Sheet at September 30, 2000, and the Consolidated Statement of Earnings for the six months ended September 30, 2000, and is qualified in its entirety by reference to such financial statements. </LEGEND> <CIK> 0000069499 <NAME> none <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> MAR-31-2001 <PERIOD-END> SEP-30-2000 <CASH> 219,339 <SECURITIES> 35,585 <RECEIVABLES> 262,411 <ALLOWANCES> 89,315 <INVENTORY> 198,391 <CURRENT-ASSETS> 685,468 <PP&E> 289,012 <DEPRECIATION> 114,056 <TOTAL-ASSETS> 1,334,213 <CURRENT-LIABILITIES> 228,914 <BONDS> 26,707 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 65,261 <OTHER-SE> 997,251 <TOTAL-LIABILITY-AND-EQUITY> 1,334,213 <SALES> 374,810 <TOTAL-REVENUES> 374,810 <CGS> 203,525 <TOTAL-COSTS> 203,525 <OTHER-EXPENSES> 111,054 <LOSS-PROVISION> 586 <INTEREST-EXPENSE> 9 <INCOME-PRETAX> (66,531) <INCOME-TAX> (23,951) <INCOME-CONTINUING> (42,580) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (42,580) <EPS-BASIC> (.34) <EPS-DILUTED> (.33)